Grace Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for neurological disorders. Founded in 2015, the company has made significant strides in advancing its proprietary drug delivery systems, particularly in the treatment of conditions such as epilepsy and other central nervous system disorders. With a commitment to enhancing patient outcomes, Grace Therapeutics offers unique formulations that improve the bioavailability and efficacy of existing medications. Their cutting-edge approach has positioned them as a leader in the biopharmaceutical industry, garnering recognition for their contributions to drug development. As they continue to expand their operational reach, Grace Therapeutics remains dedicated to transforming the landscape of neurological treatment through science and innovation.
How does Grace Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Grace Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Grace Therapeutics, Inc., headquartered in the US, currently does not have any reported carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions or reduction initiatives available, it is unclear how Grace Therapeutics, Inc. is addressing its carbon footprint or contributing to climate action within its industry. The lack of data may suggest an opportunity for the company to develop and communicate its climate commitments more effectively in the future.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grace Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.